je.st

Home › abbvie

Tag: abbvie

Abbvie 'Enhanzes' Halozyme Therapeutics coffers in potential $1.193B collaboration

2015-06-04 06:37:32| Logistics - Topix.net

Fresh off reporting good news at the American Society of Clinical Oncology annual meeting in Chicago, Halozyme Therapeutics Inc. segued into yet another global collaboration and license agreement - this time with Abbvie Inc. - that could add $1.193 billion to its coffers. The deal allows Abbvie, of North Chicago, to apply Halozyme's Enhanze delivery platform to up to nine of its compounds in return for $23 million up front to Halozyme and milestone payments totaling approximately $130 million for each collaboration target.

Tags: potential collaboration therapeutics coffers

AbbVie raises outlook as Humira again delivers earnings beat

2015-04-23 17:57:24| Biotech - Topix.net

Drugmaker AbbVie is raising its full-year earnings guidance after reporting better-than-expected first quarter adjusted results on continued growth of its blockbuster anti-inflammatory drug Humira. However, U.S. sales of the company's recently approved hepatitis C pill came in below expectations, underscoring concerns that the company is too reliant on Humira.

Tags: beat outlook delivers earnings

AbbVie to buy leukemia drugmaker Pharmacyclics for $21B

2015-03-06 06:29:46| Food - Topix.net

AbbVie will spend about $21 billion to buy fellow drugmaker Pharmacyclics and add another major revenue producer to a portfolio that already includes the world's top-selling drug. The deal will give the North Chicago, Ill., drugmaker Imbruvica, a blood cancer treatment that Pharmacyclics makes and then markets with Johnson & Johnson's Janssen Biotech.

Tags: buy leukemia 21b drugmaker

AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

2015-03-05 13:11:44| Biotech - Topix.net

AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. The deal -- the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline -- confounds expectations that Pharmacyclics would sell out to Johnson & Johnson .

Tags: deal drug cancer billion